Biopharma Analyst Chen and Biotech Analysts Kluska & Agrawal, along with Dr. Wajahat Mehal, Professor of Medicine at Yale School of Medicine, discuss new and emerging treatments for Non-Alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) (relevant companies NVO LLY MRK MDGL AKRO ETNB) on an Analyst/Industry conference call to be held on February 13 at 1 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk price target raised to DKK 950 from DKK 850 at JPMorgan
- Amgen downgraded to Market Perform from Outperform at Leerink
- Novo Nordisk price target raised to $135 from $115 at TD Cowen
- M & A News: Novo Nordisk Announces $16.5B Catalent (NYSE:CTLT) Deal
- Catalent jumps 13% to $61.46 after Novo Holdings merger agreement
Questions or Comments about the article? Write to editor@tipranks.com